NF nemzetközi konferencia 2017. 

2017 NF Conference

June 10 - 13

Renaissance Washington, DC Downtown Hotel

22
Days4
Hours23
Minutes

https://www.ctf.org/get-involved/nf-conference

https://www.cvent.com/events/2017-nf-conference/agenda-07de44bd3eb5496c9e1be57921b8f738.aspx

Largest gathering of NF scientists and clinicians

First held in 1985 as a roundtable of 20 participants, the NF Conference is now the most important scholarly gathering of the NF research and clinical communities. The NF Conference is a global event, attracting more than 300 participants worldwide across a wide range of scientific disciplines, from research and clinical backgrounds, all focused on improving outcomes for patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis. The NF Conference is a critical forum for consensus building and advancing basic, translational, and clinical research in NF and related fields, while fostering collaborations within and beyond the NF community. Importantly, the NF Conference is a key venue for attracting and growing new investigators in NF research and clinical care.

• Optional Satellite Session

  8:00 AM - 12:00 PM Educational SymposiumGrand Ballroom Central/South
  12:00 PM - 12:45 PM Lunch on Your Own
  

  Opening Remarks

  12:45 PM - 1:00 PM Opening RemarksGrand Ballroom Central/South

  Conference Co-Chairs:
  

  Rosalie Ferner, MD, Professor of Neurology, Guy's and St. Thomas' NHS Foundation Trust, and King's College London

  Lawrence Sherman, PhD, Professor, Division of Neuroscience, Oregon National Primate Research Center and Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University

  and
  

  Annette Bakker, PhD, Children's Tumor Foundation President and CSO

  Keynote #1

  1:00 PM - 2:00 PM Keynote Speech #1: Stem Cells in Silence, Action and CancerGrand Ballroom Central/SouthElaine Fuchs, PhD, Rebecca C. Lancefield Professor of Mammalian Cell Biology and Development, Rockefeller University

  Break

  2:00 PM - 2:15 PM BreakFoyer Congressional Ballroom
  

  SESSION 1

  2:15 PM - 4:15 PM Session 1: Stem Cells and NF Tumor BiologyGrand Ballroom Central/South

  Session Co-Chairs: Matthias Karajannis, MD, MS, Memorial Sloan Kettering Cancer Center; Peter deBlank, MD, MSCE, Cincinnati Children's Hospital Medical Center

  2:15pm - 2:50pm: Perspectives Talk - "The Cellular and Molecular Pathogenesis of NF1 Optic Gliomas" David Gutmann, MD, PhD, Washington University
  
  2:50pm - 3:15pm: "Roots of Neurofibromas"
  Juha Peltonen, MD, PhD, University of Turku, Finland
  
  3:15pm - 3:35pm: "The Role of MEK Inhibitors for the Prevention and Treatment of OPG in an NF1-DeficientMouse Model"
  Miriam Bornhorst, MD, Children's National Medical Center
  
  3:35pm - 3:55pm: Platform: "Differentiation of Plexiform Neurofibroma (PNF)-derived NF1(+/-) and NF1 (-/-) iPS Cells into Schwann Cells Mimicking Primary PNF Cells: Closing the Circle"
  Eduard Serra, PhD, The Institute for Health Science Research Germans Trias i Pujol (IGTP) - Program ofPredictive and Personalized Medicine of Cancer (PMPPC)

  3:55pm - 4:15pm: Platform: "Cancer Stem Cells as the Target for MPNST Tumorigenesis and Relapse"Daochun Sun, PhD, Brain Center, Memorial Sloan Kettering Cancer Center

  Poster Advertisement

  4:15 PM - 4:25 PM Poster Advertisements - Basic ScienceGrand Ballroom Central/South
  

  Poster Session

  4:30 PM - 6:00 PM Poster Session - Basic ScienceCongressional Ballroom A/B
  

  Welcome Dinner

  6:30 PM - 10:00 PM Welcome Dinner and von Recklinghausen Award Presentation

  National Press Club
  529 14th Street, NW
  Washington, DC 20045

  https://www.press.org/about/history

  Keynote Speaker: Greg Simon, JD, Executive Director, Biden Foundation, former Executive Director, White House Cancer Moonshot Initiative

  
  
• Sunday, June 11, 2017
• 7:30 AM - 9:00 AM Clinic Coordinators' Breakfast (by invitation only)City Tap House

  Please RSVP to Heather Radkte - hradtke@ctf.org.

  City Tap House
  901 9th Street, NW
  Meet in hotel lobby at 7:15am)

  
  

  Breakfast

  7:30 AM - 9:00 AM BreakfastFoyer Grand Ballroom Central/South.

  Keynote #2

  9:00 AM - 10:00 AM Keynote #2: Identifying Tumor Vulnerabilities through Integrated AnalysisGrand Ballroom Central/SouthMichael Dyer, PhD, Richard C. Shadyac Endowed Chair in Pediatric Cancer Research, St. Jude's Children's Research Center
  

  Break

  10:00 AM - 10:30 AM BreakFoyer Grand Ballroom Central/South
  

  Plenary Talk

  10:30 AM - 11:00 AM Plenary Talk: Mind the Research Science - Data Science GapGrand Ballroom Central/South

  Shasha Jumbe, PhD, Senior Program Officer, Quantitative Sciences, Bill and Melinda Gates Foundation

  SESSION 2

  11:00 AM - 12:30 PM Session 2: Genes, Genotypes and PhenotypesGrand Ballroom Central/South

  Session Chairs: Ludwine Messiaen, PhD, University of Alabama at Birmingham; Miriam Smith, PhD, University of Manchester, UK
  

  11:00 am - 11:30 am: Perspectives Talk - "Towards Genome-Guided Therapy for NF1"
  Bruce Korf, MD, PhD, University of Alabama at Birmingham
  11:30 am - 11:50am: "Mutations in Schwannomatosis"
  Laura Papi, MD, University of Florence, Italy
  11:50am - 12:10pm: "Large NF1 Deletions: Underlying Mutational Mechanisms and Genotype-Phenotype Relationships"
  Hildegard Kehrer-Sawatzki, PhD, University of Ulm, Germany
  12:10pm - 12:30pm: Platform: "Genotype-phenotype correlation in NF1 patients: evidence for a more severe phenotype associated with missense mutations affecting NF1 codons 844-848"
  Magdalena Koczkowska, PhD, Department of Genetics, University of Alabama at Birmingham
  

  12:30 PM - 1:30 PM Clinical Care Advisory Board Lunch (closed meeting)TBA
  

  Lunch

  12:30 PM - 1:30 PM LunchFoyer Grand Ballroom Central/South
  

  SESSION 3

  1:30 PM - 3:30 PM Session 3: Non-Tumor Manifestations of NFGrand Ballroom Central/South

  Session Co-Chairs: Aaron Schindeler, PhD, Children's Hospital at Westmead, AUS; Nicole Ullrich, MD, PhD, Boston Children's Hospital, Harvard University

  1:30pm - 1:50pm: "A Dietary Intervention for NF1-Associated Muscle Weakness"
  Aaron Schindeler,PhD, Children's Hospital at Westmead, AUS1:50pm - 2:10pm: "Investigating Double Inactivation of NF1 in Cases of Scoliosis"
  David Stevenson, MD, Stanford University2:10pm - 2:30pm: "Neuropathies"
  Helen Morrison, PhD, Leipzig Research Institute on Aging, Fritz Lipmann Institute, Germany2:30pm - 2:50pm: Platform: "The Reduced Osteogenic Differentiation Potential of NF1-Deficient Osteoprogenitors is EGFR-Independent"
  Seyedmohammad Ebrahim Tahaei, PhD Candidate, Pharmacology Department, Vanderbilt University

  2:50pm - 3:10pm: Platform: "Clinically Significant Neuropathy in NF2 - Frequency, Clinical and Neurophysiological Characteristics in 33 of 175 Patients Attending a National NF2 Service"
  Victoria Williams, MD, Neurofibromatosis Centre, Department of Neurology, Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London, UK

  3:10pm - 3:30pm: Platform: "Resting Metabolic Rate and Adiposity Assessment in Individuals with Neurofibromatosis Type 1: Comparing Gold Standard to Conventional Methods"
  Juliana Souza, MD, PhD, Neurofibromatosis Outpatient Reference Center, Federal University of Minas Gerais, Brazil

  Poster Advertisement

  3:30 PM - 3:40 PM Poster Advertisements - ClinicalGrand Ballroom Central/South
  

  Poster Session

  3:40 PM - 5:10 PM Poster Session - Clinical ScienceCongressional Ballroom A/B

  Wine and cheese served.

  
  

  Dinner

  5:30 PM - 8:30 PM Dinner on Your Own
  

  Mentoring

  5:30 PM - 6:30 PM "Speed-Dating": Pre and Post-Doc Mentoring SessionTBA
  
• Monday, June 12, 2017

• Breakfast

  7:00 AM - 8:30 AM BreakfastFoyer Grand Ballroom Central/South
  8:30 AM - 9:30 AM Concurrent Platform Session - 4A Clinical ScienceGrand Ballroom Central/South

  Session Chair: D. Wade Clapp, MD, Indiana University School of Medicine

  8:30am - 8:50am: Platform: "Peripheral Neuropathy - Expanding the Clinical Phenotype of Schwannomatosis"
  Matthew Evans, MRB MD, Neurofibromatosis Centre, Department of Neurology, Guy's and St. Thomas' NHS Foundation Trust, Guy's Hospital, London, UK
  

  8:50am - 9:10am: Platform: "Multiple Cancers in Neurofibromatosis Type 1"
  Roope A. Kallionpää, MSc (pharm), University of Turku, Finland

  9:10am - 9:30am: Platform: "NF1-Associated Dystrophic Scoliosis: Standardization of Diagnostic Criteria and Prediction Using Single-Nucleotide Polymorphism Markers
  Christopher L. Moertel, MD, University of Minnesota Masonic Children's Hospital
  

  8:30 AM - 9:30 AM Concurrent Platform Session - 4B Basic ScienceCongressional Ballroom C

  Session Chair: Yuan Zhu, PhD, Children's National Medical Center

  8:30am - 8:50am: Platform: "Exploiting Novel Vulnerabilities in NF1-Associated Tumorigenesis: A Small Molecule Screen Identifies Compounds Capable of Selectively Killing NF1-Deficient Human Schwann Cells"
  Kyle B. Williams, PhD, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Twin Cities

  8:50am - 9:10am: Platform: "Nonsense Suppression Rescues Lethal Phenotype in Systemic Induced NF1 Adult Mouse Harboring Patient-Specific Mutation"
  Ashley N. Turner, MS, Department of Genetics, University of Alabama at Birmingham
  9:10am - 9:30am: Platform: "Immunotherapy for MPNST"
  Thomas De Raedt, PhD, Harvard Medical School
  

  
  

  SESSION 5

  9:30 AM - 12:35 PM Session 5: NF TumorsGrand Ballroom Central/South

  Session Co-Chairs: Scott Plotkin, MD, PhD, Massachusetts General Hospital/Harvard University;Brigitte Widemann, MD, National Cancer Institute

  9:30am - 9:40am: "MPNST State of the Science: Outlining a Research Agenda for the Future"
  AeRang Kim, MD, PhD, Children's National Medical Center
  
  9:40am - 9:50am: "Introducing ANNUBP - Atypical Neurofibromatous Neoplasms of Uncertain Biologic Potential; Summary of Consensus NIH Workshop on Neurofibromas, Atypical Neurofibromas and MPNST in NF1 Patients"
  Anat Stemmer-Rachamimov, MD, Harvard University
  9:50am - 10:15am: "Defining Cutaneous Neurofibromas"
  Pierre Wolkenstein, MD, PhD, Hôpital Henri-Mondor, Universite de Paris EST Creteil; Jaishri Blakeley, MD,Johns Hopkins University Hospital

  10:15am - 10:30am: Break
  10:30am - 10:50am : "Drug Screening in Synodos for NF2"
  James Gusella, PhD, Harvard University
  10:50am - 11:10am: "Genomic Landscape of Schwannomas"
  Gelareh Zadeh, MD, University of Toronto
  11:10am - 11:30am : "Schwannoma Models"
  James Walker, PhD, Harvard University
  11:30am - 11:50am : NF Mouse Models
  Nancy Ratner, PhD, Cincinnati Children's Hospital Medical Center
  11:50am - 12:05pm: Platform: "A Phase II Prospective Study of Selumetinib in Children with Recurrent or Refractory NF1-Associated Low-Grade Glioma (LGG): A Pediatric Brain Tumor Consortium (PBTC) Study"
  Roger Packer, MD, Children's National Health System, Washington, DC
  12:05pm - 12:20pm: Platform: "NF106: A Phase 2 NF Consortium Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults with NF1-Related Plexiform Neurofibromas"
  Brian Weiss, MD, Cincinnati Children's Hospital Medical Center
  12:20pm - 12:35pm: Platform: "A Swine Model of Neurofibromatosis Type 1"
  Adrienne L. Watson, PhD, Recombinetics, Inc.
  

  Lunch

  12:35 PM - 2:00 PM Lunch and MentoringFoyer Grand Ballroom Central/South

  Location of Mentoring Tables TBA

  
  

  CONCURRENT SESSION

  2:00 PM - 4:00 PM Session 6A: Learning, Memory and Behavior through the Ages in NFGrand Ballroom Central/South

  Session Co-Chairs: Ype Elgersma, PhD, Erasmus University Medical Center, Netherlands; Eric Legius, MD, PhD, University of Leuven, Belgium

  2:00pm - 2:30pm: Perspectives Talk - "Cognition in NF through all Ages"
  Eric Legius, MD, PhD, University of Leuven, Belgium

  2:30pm - 2:50pm: "Cognition and Behavior in Neurofibromatosis Type 1: Recent Advances
  Jonathan Payne, PsyD, Murdoch Children's Research Hospital, Victoria, Australia

  2:50pm - 3:10pm: "Autism Disorder in Neurofibromatosis"
  John Constantino, MD, Washington University, St. Louis

  3:10pm - 3:30pm: Platform: "Neurofibromin Deficiency Alters Brain-Wide Intrinsic Functional Organization of the Developing Brain"
  Ben Shofty, MD, Tel Aviv Medical Center

  3:30pm - 3:50pm: Platform: "Habituation Learning in Drosophila - a High-Throughput Platform to Identify Drugs that Ameliorate Cognitive and Behavioral Problems in NF1 and Other Rasopathies"
  Michaela Fenckova, PhD, Department of Human Genetics, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands

  2:00 PM - 4:00 PM Session 6B: New Advances in NF2 and SchwannomatosisCongressional Ballroom C

  Session Co-Chairs: Marco Giovannini, MD, PhD, UCLA; Gareth Evans, MD, St. Mary's Hospital, University of Manchester, UK

  2:00pm - 2:20pm: "Characterization of SMARCB1/NF2 Mice"
  Jeremie Vitte, PhD, UCLA

  2:20pm - 2:40pm: "Prenatal Smo Activitation in Meningeal Cells is Necessary to Promote Meningothelial Meningioma of the Skull Base"
  Michel Kalamarides, MD, PhD, Hôpital de la Pitié-Salpétrière, Paris

  2:40pm - 3:00pm: "Pain Phenotypes and Mechanisms Linked to Mouse and Human SMARCB/1 Mutant Schwann Cells"
  Steven Matsumoto, PhD, Oregon Health and Science University

  3:00pm - 3:20pm: Platform: "YAP/TAZ-mediated Metabolic Reprogramming is Required for Growth and Survival of NF2-Deficient Tumor Cells in Vitro and in Vivo"
  Shannon White, BS, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center

  3:20pm - 3:40pm: Platform: "Co-Targeting mTORC1/2 and EPH Receptor Pathways as a Therapeutic Potential for NF2-Deficient Meningiomas"
  Roberta Beauchamp, BA, Massachusetts General Hospital

  3:40pm - 4:00pm: Platform: "Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis"
  Filippo Giancotti, MD, PhD, MD Anderson Cancer Center
  

  4:00 PM - 7:00 PM All Clinics MeetingMount Vernon, Meeting Room Level

  All Clinic Directors, Coordinators and Staff

  RSVP required to hradtke@ctf.org

  Click below to view agenda:

  NF Clinics Breakout Session Agenda

  Free Time

  4:00 PM - 10:30 PM Free Time and Dinner on Your Own
  
• Tuesday, June 13, 2017

• Breakfast

  7:30 AM - 9:00 AM BreakfastFoyer Grand Ballroom Central/South
  

  Poster Session

  9:00 AM - 10:00 AM Top Oral Poster Presentations and AwardsGrant Ballroom South
  

  Keynote Speech

  10:00 AM - 11:00 AM Keynote #3: Common Signaling Mechanisms in Different Forms of NFGrand Ballroom South

  Helen Morrison, PhD, ​​Leipzig Institute on Aging, Fritz Lipmann Institute, Germany

  Break

  11:00 AM - 11:15 AM Break
  

  SESSION 7

  11:15 AM - 1:15 PM Session 7: Signaling in NeurofibromatosisGrand Ballroom South

  Session Co-Chairs: Karlyne Reilly, PhD, National Cancer Institute; Alison Lloyd, PhD, University CollegeLondon, UK11:15am - 11:35am: "Role of NF1 in Reward, Motor Learning and Opioid Actions in the Striatum"
  Kirill Martemyanov, PhD, Scripps Institute

  11:35am - 11:55pm: "RASopathies in Zebrafish"
  Rebecca Burdine, PhD, Princeton University

  11:55 - 12:15pm - Platform: "The Molecular and Immunologic Landscape of Cutaneous Neurofibroma"
  Robert Allaway, PhD, Sage Bionetworks
  12:15pm - 12:35pm: "Shutting your TRAP to Kill Neurofibromas? The Oncogenic Role of the Mitochondrial Chaperone TRAP1 in NF1"
  Andrea Rasola, PhD, University of Padova, Italy
  12:35pm - 12:55pm: "Tipping the Redox Balance in the Fight against NF2"
  Chunling Yi, PhD, Lombardi Comprehensive Cancer Center, Georgetown University Medical School
  
  12:55pm - 1:15pm: "Merlin and the Hippo Signalling Pathway in the Nucleus"
  Joseph Kissil, PhD, Scripps Research Institute
  

  
  1:15 PM - 1:35 PM Session 8: Development of New Therapies for NF1 and NF2: A Model Strategy for Orphan DiseasesGrand Ballroom South

  D. Wade Clapp, MD, Indiana University School of Medicine

  NF Conference Adjourns

  1:35 PM - 1:50 PM Closing RemarksGrand Ballroom South